The Cigna Group Website

The Cigna Group

NYSE-CI

Company Overview

The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

  • Name

    The Cigna Group

  • CEO

    David Michael Cordani

  • Website

    www.thecignagroup.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    1792

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Combining with Express Scripts gave Cigna more tools to help clients control their healthcare costs, and we see significant cross-selling opportunities across their respective books of business.

  • Cigna continues to increase its focus on the relatively high-margin commercial segment, keeping it out of some of the problems associated with mismatched rates and utilization in government-sponsored programs.

  • Cigna's organic earnings growth prospects look solid both with and without capital-allocation activities, such as share repurchases.

Bears Say

  • Healthcare reform may remain a recurring political topic until universal, affordable coverage is achieved in the US, and Cigna's stock may experience volatility if scenarios that threaten its prospects gain traction.

  • Cigna faces some client concentration risk particularly in its Evernorth PBM business where the Department of Defense is its largest client and Centene recently came on board.

  • Democrats and Republicans appear to agree that the PBM industry needs to be reformed, which puts Cigna's top profit generator in the regulatory crosshairs of Congress.

Source: Morningstar Analysis - Nov 12, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

Cigna Group Faces Mixed Signals Amid Legislative Uncertainties

  • Bank of America Merrill Lynch added Cigna to its US 1 List, indicating strong potential for future performance.
  • Guggenheim raised its price target for Cigna from $309 to $318 while maintaining a Buy rating.
  • Strategic partnerships with major pharmaceutical firms aim to address pricing changes following regulatory updates.

Over the past month, Cigna Group's stock declined by 2.0%, underperforming the S&P 500's return of 0.7%. This resulted in an underperformance of -2.7% relative to the broader market index. Additionally, Cigna lagged behind the Health Care sector (XLV), where it underperformed by -3.9%. The month was characterized by both bullish and bearish sentiments influencing CI's stock movements.

A notable positive development occurred when Bank of America Merrill Lynch included Cigna on its US 1 List, suggesting strong growth potential ahead. Furthermore, Guggenheim increased its price target for the company from $309 to $318 while maintaining a Buy rating, reflecting optimism regarding Cigna’s growth prospects. Additionally, the launch of Clearity by Cigna Healthcare aimed at improving affordability in healthcare costs showcased proactive innovation within their service offerings.

Despite these encouraging indicators, bearish sentiment emerged due to concerns about proposed reforms targeting pharmacy benefit managers as part of a Republican healthcare plan. These developments raised questions about cost control measures that could negatively impact companies like Cigna in an already competitive environment. Moreover, despite some recent short-term gains—such as an increase noted on December 3—the overall trend revealed a concerning annual decline approaching nearly 17%.

Cigna’s participation in key industry conferences and collaborations with major pharmaceutical firms such as Novo Nordisk and Eli Lilly were also highlighted during this period; these partnerships seek to address pricing modifications following regulatory changes related to GLP-1 drugs. Such strategic initiatives reflect efforts made by CI management toward adapting business models amid evolving market conditions.

Cigna Group underperformed the Health Care (XLV) sector by -3.9%.

NYSE:CI